Literature DB >> 10611943

A sulfated proteoglycan aggregation factor mediates amyloid-beta peptide fibril formation and neurotoxicity.

J McLaurin1, T Franklin, W J Kuhns, P E Fraser.   

Abstract

Proteoglycans are associated with senile plaques in Alzheimer's disease and may be involved in A beta fibril formation and plaque formation. In vitro, glycosaminoglycans have been shown to inhibit the proteolysis of A beta fibrils, accelerate formation and maintain their stability. To model their interaction, we investigated the binding of a sulfated proteoglycan derived from a natural source; marine sponge Microciona prolifera aggregation factor (MAF). This species-specific re-aggregation of sponge cells has two functional properties, a Ca2+ independent cell binding activity and a Ca2+ dependent self-aggregation. It has been shown that a novel sulfated disaccharide and a pyruvylated trisaccharide are important in the Ca(2+)-dependent MAF aggregation. Aggregation demonstrated by homophilic binding of MAF subunits may be chemically distinct from other heterotypic binding effects. We investigated A beta-MAF interactions and show that MAF induces a structural transition in A beta 40 and A beta 42 from random to beta-structure as detected by circular dichroism spectroscopy. Electron microscopy revealed that the structural transition correlated with an increase in the number of A beta 40 and A beta 42 aggregated that have a truncated fibrillar morphology. Finally, MAF increased A beta-induced toxicity of nerve growth factor (NGF)-differentiated PC-12 cells in the absence of Ca2+. The addition of Ca2+ to MAF-A beta incubations resulted in a moderate attenuation of toxicity possibly due to a reduction in A beta-cell interactions caused by extensive lateral aggregation of the MAF-A beta complexes. Our results indicate that A beta is generally susceptible to proteoglycan-mediated aggregation and fibril formation. We also propose that the MAF model system may be useful in delineating these interactions and represent a means to develop and examine potential inhibitors of the proteoglycan effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10611943     DOI: 10.3109/13506129909007334

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  6 in total

1.  Metalloendoprotease cleavage triggers gelsolin amyloidogenesis.

Authors:  Lesley J Page; Ji Young Suk; Mary E Huff; Hee-Jong Lim; John Venable; John Yates; Jeffery W Kelly; William E Balch
Journal:  EMBO J       Date:  2005-11-10       Impact factor: 11.598

Review 2.  Amyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's disease.

Authors:  Elena Anahi Bignante; Florencia Heredia; Gerardo Morfini; Alfredo Lorenzo
Journal:  Neurobiol Aging       Date:  2013-05-25       Impact factor: 4.673

3.  Novel glycosaminoglycan precursors as anti-amyloid agents part II.

Authors:  Robert Kisilevsky; Walter A Szarek
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 4.  Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation.

Authors:  Katie L Stewart; Sheena E Radford
Journal:  Biophys Rev       Date:  2017-06-19

5.  Novel glycosaminoglycan precursors as anti-amyloid agents, part III.

Authors:  Robert Kisilevsky; Walter A Szarek; John Ancsin; Shridhar Bhat; Zhanjiang Li; Sandra Marone
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

6.  Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase.

Authors:  Zoe Scholefield; Edwin A Yates; Gareth Wayne; Augustin Amour; William McDowell; Jeremy E Turnbull
Journal:  J Cell Biol       Date:  2003-10-06       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.